Generation Bio Co.(GBIO)Earnings, Financials & Key Ratios
GBIO•NASDAQ
Price updated Apr 24, 2026
AboutGeneration Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$20M+236.9%
- EBITDA-$137M-3.1%
- Net Income-$132M-4.0%
- EPS (Diluted)-19.76-0.7%
- Gross Margin100%
- EBITDA Margin-691.03%+69.4%
- Operating Margin-715.82%+69.5%
- Net Margin-661.91%+69.1%
- ROE-91.02%-74.5%
GBIO Key Insights
Generation Bio Co. (GBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GBIO Price & Volume
Generation Bio Co. (GBIO) stock price & volume — 10-year historical chart
Loading chart...
GBIO Growth Metrics
Generation Bio Co. (GBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-17.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM56.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM57.33%
Return on Capital
10 Years-53.37%
5 Years-42.37%
3 Years-42.77%
Last Year-53.63%
GBIO Peer Comparison
Generation Bio Co. (GBIO) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 |
Compare GBIO vs Peers
Generation Bio Co. (GBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GBIO Income Statement
Generation Bio Co. (GBIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 36K | 0 | 0 | 0 | 0 | 5.9M | 19.89M | 15.27M |
Revenue Growth % | - | -100% | - | - | - | - | 236.92% | -17.82% |
Cost of Goods Sold | 0 | 1.86M | 3.43M | 0 | 0 | 0 | 0 | 1.4M |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 36K▲ 0% | -1.86M▼ 5277.8% | -3.43M▼ 84.1% | 0▲ 100.0% | 0▲ 0% | 5.9M▲ 0% | 19.89M▲ 236.9% | 13.87M▲ 0% |
Gross Margin % | 100% | - | - | - | - | 100% | 100% | 90.81% |
Gross Profit Growth % | - | -5277.78% | -84.12% | 100% | - | - | 236.92% | - |
Operating Expenses | 37.33M | 62.3M | 77.68M | 119.1M | 141.18M | 144.47M | 162.28M | 98.45M |
OpEx % of Revenue | 103694.44% | - | - | - | - | 2446.93% | 815.82% | - |
Selling, General & Admin | 9.18M | 12.17M | 22.58M | 33.85M | 44.46M | 50.85M | 37.78M | 37.32M |
SG&A % of Revenue | 25494.44% | - | - | - | - | 861.28% | 189.93% | - |
Research & Development | 28.15M | 50.13M | 58.53M | 85.25M | 96.72M | 93.62M | 61.3M | 60.38M |
R&D % of Revenue | 78200% | - | - | - | - | 1585.65% | 308.19% | - |
Other Operating Expenses | 0 | 0 | -3.43M | 0 | 0 | 0 | 63.2M | 1.51M |
Operating Income | -37.29M▲ 0% | -62.3M▼ 67.1% | -81.11M▼ 30.2% | -119.1M▼ 46.8% | -141.18M▼ 18.5% | -138.56M▲ 1.9% | -142.39M▼ 2.8% | -84.58M▲ 0% |
Operating Margin % | -103594.44% | - | - | - | - | -2346.93% | -715.82% | -553.92% |
Operating Income Growth % | - | -67.06% | -30.19% | -46.83% | -18.54% | 1.86% | -2.76% | - |
EBITDA | -36.95M | -60.44M | -77.68M | -114.57M | -136.05M | -133.3M | -137.46M | -79.73M |
EBITDA Margin % | -102630.56% | - | - | - | - | -2257.79% | -691.03% | -522.15% |
EBITDA Growth % | - | -63.58% | -28.53% | -47.48% | -18.75% | 2.02% | -3.12% | 47.6% |
D&A (Non-Cash Add-back) | 347K | 1.86M | 3.43M | 4.53M | 5.13M | 5.26M | 4.93M | 4.85M |
EBIT | -37.29M | -62.3M | -80.52M | -119.1M | -141.18M | -138.56M | -79.19M | -63.35M |
Net Interest Income | 1.49M | 0 | 0 | 137K | 0 | 11.95M | 10.72M | 7.17M |
Interest Income | 1.49M | 0 | 591K | 187K | 4.54M | 11.95M | 10.72M | 7.17M |
Interest Expense | 0 | 0 | 591K | 50K | 4.54M | 0 | 0 | 0 |
Other Income/Expense | 1.49M | 985K | 591K | -50K | 4.54M | 11.95M | 10.72M | 21.96M |
Pretax Income | -35.8M▲ 0% | -61.32M▼ 71.3% | -80.52M▼ 31.3% | -119.15M▼ 48.0% | -136.64M▼ 14.7% | -126.61M▲ 7.3% | -131.67M▼ 4.0% | -62.63M▲ 0% |
Pretax Margin % | -99452.78% | - | - | - | - | -2144.51% | -661.91% | -410.13% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -35.8M▲ 0% | -60.33M▼ 68.5% | -80.52M▼ 33.5% | -119.15M▼ 48.0% | -136.64M▼ 14.7% | -126.61M▲ 7.3% | -131.67M▼ 4.0% | -62.63M▲ 0% |
Net Margin % | -99452.78% | - | - | - | - | -2144.51% | -661.91% | -410.13% |
Net Income Growth % | - | -68.51% | -33.47% | -47.97% | -14.68% | 7.34% | -3.99% | 56.95% |
Net Income (Continuing) | -35.8M | -61.32M | -80.52M | -119.15M | -136.64M | -126.61M | -131.67M | -62.63M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -18.20▲ 0% | -13.10▲ 28.0% | -29.54▼ 125.5% | -21.17▲ 28.3% | -23.51▼ 11.1% | -19.63▲ 16.5% | -19.76▼ 0.7% | -9.30▲ 0% |
EPS Growth % | - | 28.02% | -125.5% | 28.33% | -11.05% | 16.5% | -0.66% | 57.33% |
EPS (Basic) | -18.20 | -13.10 | -29.54 | -21.17 | -23.51 | -19.63 | -19.76 | - |
Diluted Shares Outstanding | 1.97M | 4.62M | 2.73M | 5.63M | 5.81M | 6.45M | 6.66M | 6.74M |
Basic Shares Outstanding | 1.97M | 4.62M | 2.73M | 5.63M | 5.81M | 6.45M | 6.66M | 6.74M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
GBIO Balance Sheet
Generation Bio Co. (GBIO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 76.93M | 18.16M | 267.74M | 379.19M | 287.02M | 272.62M | 192.9M | 93.46M |
Cash & Short-Term Investments | 74.87M | 15.08M | 262.33M | 375.14M | 279.09M | 264.36M | 185.22M | 89.62M |
Cash Only | 7.3M | 15.08M | 62.89M | 375.14M | 93.17M | 66.45M | 76.3M | 21.94M |
Short-Term Investments | 67.56M | 0 | 199.44M | 0 | 185.92M | 197.92M | 108.92M | 67.68M |
Accounts Receivable | 1.29M | 448K | 0 | 0 | 660K | 4.15M | 1.56M | 391K |
Days Sales Outstanding | 13.06K | - | - | - | - | 256.44 | 28.61 | 21.5 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 54K | 55K | 0 | 0 | 259K | 423K | 2.58M | 3.45M |
Total Non-Current Assets | 6.59M | 23.98M | 26.42M | 97.58M | 89.25M | 102.14M | 38.29M | 28.43M |
Property, Plant & Equipment | 4.49M | 21.84M | 23.78M | 91.03M | 81.42M | 95.65M | 35.6M | 26.28M |
Fixed Asset Turnover | 0.01x | - | - | - | - | 0.06x | 0.56x | 0.48x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 2.11M | 2.05M | 0 | 0 | 0 | 5.79M | 0 | 2.15M |
Other Non-Current Assets | 0 | 87K | 2.64M | 6.56M | 7.83M | 698K | 2.69M | 2.15M |
Total Assets | 83.52M▲ 0% | 42.14M▼ 49.5% | 294.15M▲ 598.0% | 476.77M▲ 62.1% | 376.26M▼ 21.1% | 374.76M▼ 0.4% | 231.2M▼ 38.3% | 121.9M▲ 0% |
Asset Turnover | 0.00x | - | - | - | - | 0.02x | 0.09x | 0.08x |
Asset Growth % | - | -49.54% | 598.04% | 62.08% | -21.08% | -0.4% | -38.31% | -151.24% |
Total Current Liabilities | 6.55M | 9.16M | 11.22M | 18.81M | 19.15M | 39.91M | 35.05M | 21.04M |
Accounts Payable | 1.68M | 2.25M | 267K | 2.02M | 662K | 2.35M | 1.41M | 2.06M |
Days Payables Outstanding | - | 440.78 | 28.4 | - | - | - | - | 517.73 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 4K | 1.37M | 1.39M | 0 | 0 | 12.92M | 10.58M | 14.35M |
Other Current Liabilities | 0 | 2.28M | 702K | 8.26M | 8.4M | 1.24M | 8.63M | 12.47M |
Current Ratio | 11.74x | 1.98x | 23.86x | 20.16x | 14.99x | 6.83x | 5.50x | 4.44x |
Quick Ratio | 11.74x | 1.98x | 23.86x | 20.16x | 14.99x | 6.83x | 5.50x | 4.44x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -496.23 |
Total Non-Current Liabilities | 118.56M | 131.57M | 14.92M | 76.22M | 74.62M | 131.72M | 109.94M | 50.3M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 76.22M | 74.62M | 89.77M | 80.55M | 253.98M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | -41.94M | 0 | 0 |
Other Non-Current Liabilities | 115.59M | 115.59M | 0 | 0 | 0 | 41.94M | 223K | 0 |
Total Liabilities | 125.11M | 140.73M | 26.14M | 95.03M | 93.77M | 171.63M | 144.99M | 71.34M |
Total Debt | 0 | 0 | 0 | 80.83M | 81.71M | 97.89M | 93.56M | 26.1M |
Net Debt | -7.3M | -15.08M | -62.89M | -294.32M | -11.46M | 31.45M | 17.26M | 4.16M |
Debt / Equity | - | - | - | 0.21x | 0.29x | 0.48x | 1.09x | 0.52x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.33x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.05x |
Interest Coverage | - | - | -137.25x | -2382.02x | -31.08x | - | - | - |
Total Equity | -41.59M▲ 0% | -98.59M▼ 137.1% | 268.01M▲ 371.8% | 381.75M▲ 42.4% | 282.49M▼ 26.0% | 203.13M▼ 28.1% | 86.2M▼ 57.6% | 50.56M▲ 0% |
Equity Growth % | - | -137.05% | 371.84% | 42.44% | -26% | -28.09% | -57.56% | -206.72% |
Book Value per Share | -21.12 | -21.33 | 98.33 | 67.81 | 48.61 | 31.50 | 12.94 | 7.51 |
Total Shareholders' Equity | -41.59M | -98.59M | 268.01M | 381.75M | 282.49M | 203.13M | 86.2M | 50.56M |
Common Stock | 1K | 1K | 5K | 6K | 6K | 7K | 7K | 1K |
Retained Earnings | -47.13M | -108.45M | -188.97M | -308.13M | -444.76M | -571.38M | -703.04M | -744.29M |
Treasury Stock | -5.55M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -9K | -115.59M | 9K | 0 | -83K | 274K | 159K | 8K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GBIO Cash Flow Statement
Generation Bio Co. (GBIO) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -28.12M | -40.35M | -70.14M | -91.82M | -102.45M | -52.74M | -88.56M | -113.65M |
Operating CF Margin % | -78108.33% | - | - | - | - | -893.38% | -445.22% | - |
Operating CF Growth % | - | -43.48% | -73.85% | -30.91% | -11.57% | 48.52% | -67.91% | -100.31% |
Net Income | -35.8M | -61.32M | -80.52M | -119.15M | -136.64M | -126.61M | -131.67M | -62.63M |
Depreciation & Amortization | 347K | 1.86M | 3.43M | 4.53M | 5.13M | 5.26M | 4.93M | 4.85M |
Stock-Based Compensation | 3.49M | 4.21M | 8.41M | 17.86M | 24.45M | 24.34M | 14.61M | 8.84M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -834K | -327K | 249K | 766K | 3.56M | -9.27M | 54.99M | -22.37M |
Working Capital Changes | 4.68M | 15.23M | -1.71M | 4.17M | 1.05M | 53.54M | -31.43M | -42.35M |
Change in Receivables | -1.29M | 840K | 448K | 0 | -395K | -3.56M | -1.22M | 1.82M |
Change in Inventory | 0 | 0 | -448K | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 223K | 761K | -1.44M | 1.76M | -1.39M | 1.09M | -386K | 418K |
Cash from Investing | -69.76M | 47.98M | -205.2M | 193.05M | -192.51M | -9.7M | 94.53M | 113.72M |
Capital Expenditures | -3.02M | -19.99M | -5.52M | -5.96M | -8.8M | -7.4M | -2.4M | -1.08M |
CapEx % of Revenue | 8391.67% | - | - | - | - | 125.29% | 12.07% | 7.09% |
Acquisitions | 0 | 80K | 199.68M | 105K | 0 | 0 | 196K | 492K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | -66.74M | 0 | -199.68M | 105K | 0 | 0 | 0 | 30K |
Cash from Financing | 100.19M | 78K | 323.1M | 214.67M | 12.99M | 35.82M | 250K | 215K |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 1000K | 100K | 1000K | 1000K | 1000K | 1000K | 436K | 232K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -22K | 341K | 2.79M | -581K | -183K | -186K | -17K |
Net Change in Cash | 2.31M▲ 0% | 7.77M▲ 236.6% | 47.76M▲ 514.5% | 315.9M▲ 561.5% | -281.97M▼ 189.3% | -26.63M▲ 90.6% | 6.22M▲ 123.3% | 283K▲ 0% |
Free Cash Flow | -31.14M▲ 0% | -60.33M▼ 93.7% | -75.66M▼ 25.4% | -97.78M▼ 29.2% | -111.25M▼ 13.8% | -60.14M▲ 45.9% | -90.96M▼ 51.2% | -114.73M▲ 0% |
FCF Margin % | -86500% | - | - | - | - | -1018.67% | -457.29% | -751.38% |
FCF Growth % | - | -93.74% | -25.41% | -29.23% | -13.78% | 45.94% | -51.25% | -9.94% |
FCF per Share | -15.81 | -13.06 | -27.76 | -17.37 | -19.14 | -9.33 | -13.65 | -17.03 |
FCF Conversion (FCF/Net Income) | 0.79x | 0.67x | 0.87x | 0.77x | 0.75x | 0.42x | 0.67x | 1.83x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GBIO Key Ratios
Generation Bio Co. (GBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -95.06% | -36.68% | -41.14% | -52.14% | -91.02% | -94.82% |
Return on Invested Capital (ROIC) | - | -133.04% | -61.07% | -59.08% | -41.11% | -63.18% | -70.78% |
Gross Margin | - | - | - | - | 100% | 100% | 90.81% |
Net Margin | - | - | - | - | -2144.51% | -661.91% | -410.13% |
Debt / Equity | - | - | 0.21x | 0.29x | 0.48x | 1.09x | 0.52x |
Interest Coverage | - | -137.25x | -2382.02x | -31.08x | - | - | - |
FCF Conversion | 0.67x | 0.87x | 0.77x | 0.75x | 0.42x | 0.67x | 1.83x |
Revenue Growth | -100% | - | - | - | - | 236.92% | -17.82% |
Related:GBIO Dividend History·GBIO Revenue History·GBIO Price History·GBIO P/E History·GBIO Financial Ratios·GBIO Institutional Holders
GBIO Frequently Asked Questions
Generation Bio Co. (GBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Generation Bio Co. (GBIO) reported $15.3M in revenue for fiscal year 2024. This represents a 42317% increase from $0.0M in 2018.
Generation Bio Co. (GBIO) grew revenue by 236.9% over the past year. This is strong growth.
Generation Bio Co. (GBIO) reported a net loss of $62.6M for fiscal year 2024.
Dividend & Returns
Generation Bio Co. (GBIO) has a return on equity (ROE) of -91.0%. Negative ROE indicates the company is unprofitable.
Generation Bio Co. (GBIO) had negative free cash flow of $114.7M in fiscal year 2024, likely due to heavy capital investments.